Alerts will be sent to your verified email
Verify EmailPARMAX
Parmax Pharma
|
Ortin Global
|
Venmax Drugs&Pharma
|
|
---|---|---|---|
Operational Metrics
|
|||
Financials
|
|||
5 yr Average ROE
|
-1624.87 % | -57.26 % | -44.32 % |
5yr average Equity Multiplier
|
46.04 | 2.67 | -0.19 |
5yr Average Asset Turnover Ratio
|
0.95 | 0.6 | 0.32 |
5yr Avg Net Profit Margin
|
-9.48 % | -75.26 % | -30.94 % |
Price to Book
|
0.0 | 6.58 | 2.96 |
P/E
|
0.0 | 0.0 | 0.0 |
5yr Avg Cash Conversion Cycle
|
-161.05 Days | 597.13 Days | 0.0 |
Inventory Days
|
73.65 Days | 335.19 Days | 24.83 Days |
Days Receivable
|
40.27 Days | 448.05 Days | 0.0 |
Days Payable
|
328.05 Days | 649.97 Days | 189.56 Days |
5yr Average Interest Coverage Ratio
|
1.16 | -2.05 | -318.36 |
5yr Avg ROCE
|
-9.94 % | -24.19 % | -45.33 % |
5yr Avg Operating Profit Margin
|
3.93 % | -55.65 % | -50.41 % |
5 yr average Debt to Equity
|
17.42 | 0.64 | -0.64 |
5yr CAGR Net Profit
|
n/a | 44.41 % | n/a |
5yr Average Return on Assets
|
-6.43 % | -20.66 % | 187.49 % |
Shareholdings
|
|||
Promoter Holding
|
30.8 % | 1.23 % | 23.13 % |
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
Change in Promoter Holding (3 Yrs)
|
0.0 | -14.45 % | 0.0 |
Change in Mutual Fund Holding (3 Yrs)
|
0.0 | 0.0 | 0.0 |
Parmax Pharma
|
Ortin Global
|
Venmax Drugs&Pharma
|
|
---|---|---|---|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|